You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A simple assay system for rapid detection of circulating tumor cells

    SBC: TELOVISION, LLC            Topic: NCI

    DESCRIPTION provided by applicant Metastasis or dissemination of primary tumor cells is the major cause of mortality in cancer patients Circulating tumor cells CTCs in the bloodstream are key players in the establishment of metastatic tumors Recent studies demonstrated that the number of CTCs present in patient blood directly correlate with cancer progression recurrence and survival rate ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery

    SBC: DISCOVERYBIOMED, INC.            Topic: NIDCD

    Principal Investigators for Small BusinessDiscoveryBioMedIncDBMand Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming global public health challengesfood insecuritypoor nutritional healthand poor compliance with medication useparticularly among children and the elderlySugar and saltthe mainstays to address these challengesfur ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Chronic intrapulmonary delivery of a novel small molecule Wnt/beta-catenin inhibitor for Idiopathic Pulmonary Fibrosis

    SBC: BETA CAT PHARMACEUTICALS, INC.            Topic: NHLBI

    Project Summary Idiopathic pulmonary fibrosisIPFis a devastatingprogressive disease with no known cure and no treatment that convincingly alters the disease course or significantly improves mortalityThe objective of this proposal is the development of nebulized delivery of the small molecule inhibitor of Wntcatenin signalingBCfor Idiopathic Pulmonary FibrosisPre clinical studies in rodentsdogsand ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Commercialization of a Rapid Blood Test for Traumatic Brain Injury

    SBC: Fawkes Biotechnology, LLC            Topic: 100

    Traumatic brain injuryTBIis a substantial health care issue affecting both civilian and military populationsAlthough extremes of head injury are recognizablemild to moderate TBImmTBIis more difficult to diagnose leading to a need for the identification of circulating biomarkers of brain injury that may facilitate early identificationUsing a rat model of TBI we identified a novel marker of neuronal ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Novel Clinical Diagnostic Assay for Peripheral T-cell Lymphoma (PTCL)

    SBC: HEALTHCHART LLC            Topic: 102

    Project Summary Abstract Peripheral T cell lymphomaPTCLis a heterogeneous cancer that constitutes up toof all non Hodgkin lymphomaNHLThe World Health Organization classification recognizes a number of distinct subtypes of PTCL but the diagnosis of these different subtypes is challenging even for expert hematopathologistsFurthermoreof PTCL cases are not classifiable into any specific subtype at all ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Compounds for the Prevention and Treatment of Rhabdomyolysis

    SBC: Virtual Drug Development Inc.            Topic: NIDDK

    ? DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to establish the feasibility of developing a small-molecule therapeutic agent designed to prevent rhabdomyolysis-induced renal failure. Rhabdomyolysis accounts for 7% to 10% of cases of renal failure in the US. Rhabdomyolysis results from muscle injury that leads to the release of myoglobin, which is then deposited ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of fully integrated electrochemical device for detecting metals in biological fluids

    SBC: Bioanalytical Systems, Inc.            Topic: NIEHS

    Exposure to toxic levels of metals causes significant negative chronic health problems in the exposed populationsDuring and after exposuremetals such as manganeseleadnickelmercuryetcare present in biological fluidsA fully integrated wearable device would enable real time monitoring of exposure levelsThis would quickly alert those exposed to toxic concentrations of metals and mitigate the chronic h ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Enhancing mtDNA Repair During Stroke Reperfusion to Reduce Brain Damage

    SBC: EXSCIEN CORPORATION            Topic: NINDS

    DESCRIPTION (provided by applicant): Attempts to develop drug treatments for acute stroke have not fulfilled expectations. Perhaps best illustrating this unsatisfactory situation is the hisory of therapeutic strategies directed at the inhibition of reactive oxygen species (ROS). While decades of laboratory and clinical studies make it clear that ROS are pathogenically important across the entire s ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluating Synthetic Biology Produced Triterpene Oils in Adjuvant Formulations

    SBC: Enepret Incorporated            Topic: NIAID

    ABSTRACT Vaccine adjuvants help stimulate the body to generate an immune response when co injected with an antigenthe compound for which immunity is desiredAlthough the human body is capable of producing antibodies to most injected antigensadjuvants can help boost the body s ability to mount a successful and acquired immune response to the presented targetAdjuvants have been shown to enhance immun ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Exosomal drug formulations

    SBC: 3P BIOTECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): More people in the U.S. (160,340 per year) die of lung cancer than of prostate, breast, and colon cancer combined. The most common type of lung cancer, non-small-cell lung cancer (NSCLC), accounts for 75% of all lung cancers. Regrettably, 85% of all patients diagnosed with NSCLC eventually die of the disease within 5 years, due to micro-metastasis and relapse. ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government